糖尿病性心肌病
脂毒性
内科学
内分泌学
过氧化物酶体
CD36
胰岛素抵抗
下调和上调
神经酰胺
心肌病
过氧化物酶体增殖物激活受体
脂质代谢
活性氧
胰岛素受体
脂滴
生物
β氧化
胰岛素
化学
受体
生物化学
新陈代谢
医学
心力衰竭
细胞凋亡
基因
作者
Ellen Dirkx,Robert W. Schwenk,Jan F. C. Glatz,Joost J.F.P. Luiken,Guillaume J.J.M. van Eys
标识
DOI:10.1016/j.plefa.2011.04.018
摘要
In response to a chronic high plasma concentration of long-chain fatty acids (FAs), the heart is forced to increase the uptake of FA at the cost of glucose. This switch in metabolic substrate uptake is accompanied by an increased presence of the FA transporter CD36 at the cardiac plasma membrane and over time results in the development of cardiac insulin resistance and ultimately diabetic cardiomyopathy. FA can interact with peroxisome proliferator-activated receptors (PPARs), which induce upregulation of the expression of enzymes necessary for their disposal through mitochondrial β-oxidation, but also stimulate FA uptake. This then leads to a further increase in FA concentration in the cytoplasm of cardiomyocytes. These metabolic changes are supposed to play an important role in the development of cardiomyopathy. Although the onset of this pathology is an increased FA utilization by the heart, the subsequent lipid overload results in an increased production of reactive oxygen species (ROS) and accumulation of lipid intermediates such as diacylglycerols (DAG) and ceramide. These compounds have a profound impact on signaling pathways, in particular insulin signaling. Over time the metabolic changes will introduce structural changes that affect cardiac contractile characteristics. The present mini-review will focus on the lipid-induced changes that link metabolic perturbation, characteristic for type 2 diabetes, with cardiac remodeling and dysfunction.
科研通智能强力驱动
Strongly Powered by AbleSci AI